New pill could ease severe asthma attacks

NCT ID NCT05748600

Disease control Sponsor: Areteia Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This Phase 3 trial tests dexpramipexole, an oral tablet, as an add-on treatment for people with eosinophilic asthma that is not well controlled. About 600 participants aged 12 and older will receive either the drug or a placebo for 24 weeks. The study measures improvements in lung function, asthma control, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: dexpramipexole
What this could lead to: If successful, this could provide a new oral treatment option for people with eosinophilic asthma that is not well controlled by current therapies.
What could go wrong: This is a Phase 3 trial, but results are not yet available. The drug may not prove effective or could have side effects. It is tested as an add-on, not a replacement for existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2023

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Signed informed consent form and assent form, as appropriate. 2. Male or female ≥12 years of age at Screening Visit 1. Sites in Poland will only include participants aged ≥18 years. Asthma-related criteria 3. Documented physician diagnosis of asthma for ≥12 months prior to Screening Visit 1. 4. Participants requiring at a minimum daily low dose inhaled corticosteroids (ICS; ≥100 μg/day fluticasone propionate dry powder formulation daily or clinically comparable, per GINA 2021), plus one or more additional daily maintenance asthma controller medications, eg, long-acting β2 agonist (LABA), leukotriene antagonist, theophylline, long-acting muscarinic antagonists, cromolyn/nedocromil. Note: In Poland, this will instead include participants requiring a minimum daily medium dose ICS (≥500 μg/day fluticasone propionate dry powder formulation daily or clinically comparable, per GINA 2021). Use of daily ICS must be for at least 12 weeks prior to Screening Visit 1 and the doses of all controller medications must be stable for at least 4 weeks prior to Screening Visit 1. 5. Pre-BD FEV1 ≥40% and \<80% (\<90% for participants 12 to 17 years of age) of predicted at Screening Visit 2. 6. Bronchodilator reversibility, at Screening Visit 2, as evidenced by ≥12% and ≥200 mL improvement in FEV1, 15 to 30 minutes following inhalation of 400 μg (four puffs) of albuterol/salbutamol (≥12% and ≥160 mL for ages 12 to 17).Participants who do not meet the bronchodilator reversibility inclusion criterion but have ≥10% and ≥160 mL reversibility, may repeat the reversibility spirometry assessment once during the Screening Period, at an unscheduled visit at least 7 days prior to baseline. 7. ACQ-6 ≥1.5 at Screening Visit 2. 8. Eosinophil count of ≥0.30x10⁹/L at Screening Visit 1. If the initial value is between 0.250x10⁹/L to 0.299x10⁹/L, then this may be repeated once at an unscheduled visit (prior to Screening Visit 2). General medical history 9. Negative urine pregnancy test for women of childbearing potential (WOCBP; after menarche) at the Screening and Baseline visits. 10. WOCBP must use either of the following methods of birth control, from Screening Visit 1 through the End of Study Visit: 1. A highly effective form of birth control (confirmed by the investigator). Highly effective forms of birth control include: true sexual abstinence, a vasectomized sexual partner, Implanon, female sterilization by tubal occlusion, any effective intrauterine device (IUD), IUD/intrauterine system (IUS), Levonorgestrel Intrauterine system, or oral contraceptive. Or 2. Two protocol acceptable methods of contraception in tandem. * Women not of childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are postmenopausal. Women will be considered postmenopausal if they have been amenorrheic for 12 months prior to the planned date of the Baseline Visit without an alternative medical cause. The following age specific requirements apply: 3. Women \<50 years old will be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatment and follicle stimulating hormone levels in the postmenopausal range. 4. Women ≥50 years old will be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatment. least 7 days prior to baseline. Exclusion Criteria: Asthma-related criteria 1. A participant who experiences a severe asthma exacerbation (defined as a deterioration of asthma that results in emergency treatment, hospitalization prior to the Screening Visit 1 up to and including the Baseline Visit. Participants who experience an asthma exacerbation during the Screening/Run-in Period may remain in screening and proceed with study visits 14 days after they have completed their course of oral steroids or returned to their pre-Screening visit maintenance dose of oral steroids and the investigator considers participant has returned to baseline status. 2. Current diagnosis of diseases which may confound interpretation of this study's findings such as allergic bronchopulmonary aspergillosis, eosinophilic granulomatosis with polyangiitis, eosinophilic gastrointestinal diseases, or hypereosinophilic syndrome, or lung diseases (eg, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis). 3. Respiratory infection: Upper or lower respiratory tract, sinus, or middle ear infection within the 4 weeks before Screening Visit 1. Prohibited medications/procedures 4. Treatment with a biologic investigational drug in the last 5 months prior to Screening Visit 1. Treatment with non-biologic investigational drugs in the previous 30 days or five-half-lives prior to Screening Visit 1, whichever is longer. Treatment with GSK3511294 (long acting anti-interleukin-5) in the past 12 months. 5. Treatment with any of the following monoclonal antibody therapies within 120 days prior to Baseline: benralizumab, dupilumab, mepolizumab, reslizumab, omalizumab, tezepelumab, or tralokinumab. 6. Treatment with pramipexole (Mirapex®) within 30 days of Baseline. 7. Treatment with selected drugs known to have a substantial risk of neutropenia in the past 30 days prior to Screening Visit 1. 8. Bronchial thermoplasty procedure in the past 12 months prior to Screening Visit 1 or planned during the study period. General medical history 9. Weight \<40 kg at Screening Visit 2. 10. Current smoking within 12 months prior to Screening Visit 1 or a smoking history of \>10 packyears. Smoking includes tobacco, vaping, and/or marijuana use. 11. Known or suspected alcohol or drug abuse. 12. Uncontrolled severe hypertension: systolic blood pressure \>180 mmHg or diastolic blood pressure \>110 mmHg prior to the Baseline Visit despite antihypertensive therapy. 13. History of malignancy that required surgery (excluding local and wide-local excision), radiation therapy and/or systemic therapy during the 5 years prior to the Baseline Visit. 14. History of human immunodeficiency virus (HIV) infection or chronic infection with hepatitis B or C. 15. A helminth parasitic infection diagnosed within 24 weeks prior to Screening Visit 1, that has not been treated with or has failed to respond to standard of care therapy. 16. Medical or other condition likely to interfere with participant's ability to undergo study procedures, adhere to visit schedule, or comply with study requirements. 17. Known or suspected noncompliance with medication. 18. Unwillingness or inability to follow the procedures outlined in the protocol. Clinical safety labs 19. Absolute neutrophil count \<2.000x10⁹/L at Screening Visit 1 or Screening Visit 2.. 20. Renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73m2 at Screening Visit 2 (using the Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] formula \[Levey et al, 2009\] for age ≥18 years at screening; using the Bedside Schwartz \[Schwartz and Work, 2009\] eGFR formula for age \<18). 21. Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained elevations in alanine aminotransferase (ALT), aspartate aminotransferase (AST), \>3x the upper limit of normal (ULN), or total bilirubin \>2x ULN at Screening Visit 2 confirmed by a repeat abnormal measurement of the relevant value(s), at least 1 week apart. Cardiac safety 22. History of New York Heart Association class IV heart failure or last known left ventricular ejection fraction \<25%. 23. History of major adverse cardiovascular event (MACE) within 3 months prior to the Baseline Visit. 24. History of cardiac arrhythmia within 3 months prior to the Baseline Visit that is not controlled by medication or via ablation. 25. History of long QT syndrome. 26. Corrected QT interval by Fridericia (QTcF) interval \>450 ms for males and \>470 ms for females at Screening Visit 2 or QTcF ≥480 ms for participants with bundle branch block. 27. Clinically important abnormalities in resting ECG that may interfere with the interpretation of QTcF interval changes at Screening Visit 2, including resting heart rate \<45 beats per minute (bpm) or \>100 bpm. Pregnancy/Lactation 28. Pregnant women or women breastfeeding. 29. Males who are unwilling to use an acceptable method of birth control during the entire study period (ie, condom with spermicide). For this study, rescreening may only be permitted under specific circumstances and only after contact with a Sponsor Clinical representative.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute asthma allergic asthma asthma pulmonary eosinophilia T2-high asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma attack Asthma; eosinophilic Eosinophilic asthma

Contacts and locations

Locations

Research Site 30043-013

Salzburg, 5020, Austria
Research Site 30060-006

Kampung Kelantan, Malaysia
Research Site 30066-004

Pathum Thani, 12120, Thailand
Research Site 30082-024

Bucheon-si, 14584, South Korea
Research Site 30090-020

Durban, 4001, South Africa
Research Site 40001-001

Miami, Florida, 33135, United States
Research Site 40001-002

Kissimmee, Florida, 34746, United States
Research Site 40001-003

West Covina, California, 91790, United States
Research Site 40001-004

Tampa, Florida, 33607, United States
Research Site 40001-005

Brandon, Florida, 33511, United States
Research Site 40001-006

Flint, Michigan, 48504, United States
Research Site 40001-010

Cincinnati, Ohio, 45236, United States
Research Site 40001-013

Cincinnati, Ohio, 45219, United States
Research Site 40001-014

Greenacres City, Florida, 33467, United States
Research Site 40001-015

Kissimmee, Florida, 34744, United States
Research Site 40001-017

Dayton, Ohio, 45424, United States
Research Site 40001-018

Columbus, Georgia, 31904, United States
Research Site 40001-019

Owensboro, Kentucky, 42301, United States
Research Site 40001-020

Homestead, Florida, 33030, United States
Research Site 40001-023

Dallas, Texas, 75230, United States
Research Site 40001-024

Miami, Florida, 33184, United States
Research Site 40001-025

Greenville, South Carolina, 29651, United States
Research Site 40001-026

Miami, Florida, 33155, United States
Research Site 40001-027

Grants Pass, Oregon, 97527, United States
Research Site 40001-028

Dallas, Texas, 75235, United States
Research Site 40001-029

Coral Gables, Florida, 33134, United States
Research Site 40001-032

Columbia, South Carolina, 29204, United States
Research Site 40001-034

Cincinnati, Ohio, 45215, United States
Research Site 40001-036

Elwood, Indiana, 46036, United States
Research Site 40001-039

Gastonia, North Carolina, 28054, United States
Research Site 40001-043

Newport Beach, California, 92663, United States
Research Site 40001-046

St Louis, Missouri, 63110, United States
Research Site 40001-047

Hawthorne, New York, 10532, United States
Research Site 40001-048

Aventura, Florida, 33180, United States
Research Site 40001-050

East Amherst, New York, 14051, United States
Research Site 40001-051

Brandon, Florida, 33511, United States
Research Site 40001-054

Hialeah, Florida, 33012, United States
Research Site 40001-055

White Marsh, Maryland, 21162, United States
Research Site 40001-059

Miami, Florida, 33144, United States
Research Site 40001-062

Newport Beach, California, 92660, United States
Research Site 40001-063

Toledo, Ohio, 43617, United States
Research Site 40001-064

Houston, Texas, 77074, United States
Research Site 40001-065

Miami, Florida, 33173, United States
Research Site 40001-066

Miami, Florida, 33126, United States
Research Site 40001-067

Hialeah, Florida, 33016, United States
Research Site 40001-068

Amarillo, Texas, 79124, United States
Research Site 40001-069

St. Petersburg, Florida, 33713, United States
Research Site 40001-073

Spartanburg, South Carolina, 29303, United States
Research Site 40001-074

Saint Charles, Missouri, 63301, United States
Research Site 40001-075

Augusta, Georgia, 30909, United States
Research Site 40001-079

Oklahoma City, Oklahoma, 73120, United States
Research Site 40001-083

Columbia, Missouri, 65203, United States
Research Site 40001-085

Houston, Texas, 77099, United States
Research Site 40001-086

Loxahatchee Groves, Florida, 33470, United States
Research Site 40001-088

San Jose, California, 95117, United States
Research Site 40001-089

Los Angeles, California, 90048, United States
Research Site 40001-090

Berwyn, Illinois, 60402, United States
Research Site 40001-111

Huntersville, North Carolina, 28078, United States
Research Site 40001-135

River Forest, Illinois, 60305, United States
Research Site 40001-142

Adairsville, Georgia, 30103, United States
Research Site 40001-148

Flint, Michigan, 48507, United States
Research Site 40001-227

Encinitas, California, 92024, United States
Research Site 40001-258

Murray, Utah, 84107, United States
Research Site 40001-283

Winston-Salem, North Carolina, 21704, United States
Research Site 40001-288

Miami, Florida, 33165, United States
Research Site 40001-293

Orlando, Florida, 32819, United States
Research Site 40001-295

McKinney, Texas, 75069, United States
Research Site 40001-304

DeSoto, Texas, 75115, United States
Research Site 40001-304

Red Oak, Texas, 75154, United States
Research Site 40001-313

Marrero, Louisiana, 70072, United States
Research Site 40001-318

Maitland, Florida, 32751, United States
Research Site 40001-319

Viera, Florida, 32940, United States
Research Site 40001-322

Surprise, Arizona, 85378, United States
Research Site 40001-327

Philadelphia, Pennsylvania, 19140, United States
Research Site 40001-333

Pleasant View, Utah, 84404, United States
Research Site 40001-334

Allen, Texas, 75013, United States
Research Site 40001-335

Sugar Land, Texas, 77479, United States
Research Site 40001-337

Portland, Oregon, 97202, United States
Research Site 40001-338

Miami Beach, Florida, 33169, United States
Research Site 40001-339

Greenfield, Wisconsin, 53228, United States
Research Site 40001-340

Burke, Virginia, 22015, United States
Research Site 40001-343

Chicago, Illinois, 60607, United States
Research Site 40001-347

Louisville, Kentucky, 40202, United States
Research Site 40001-348

Ocala, Florida, 34471, United States
Research Site 40001-349

Huntington Beach, California, 92647, United States
Research Site 40001-350

Gainesville, Florida, 32607, United States
Research Site 40001-351

Sarasota, Florida, 34239, United States
Research Site 40001-352

Zachary, Louisiana, 70791, United States
Research Site 40001-353

Colorado Springs, Colorado, 80907, United States
Research Site 40001-355

Toms River, New Jersey, 08755, United States
Research Site 40001-357

Lancaster, California, 93534, United States
Research Site 40001-358

Normal, Illinois, 61761, United States
Research Site 40001-359

Upland, California, 91756, United States
Research Site 40001-362

Mission Viejo, California, 92691, United States
Research Site 40001-363

Edison, New Jersey, 08817, United States
Research Site 40001-366

Lilburn, Georgia, 30047, United States
Research Site 40001-369

New York, New York, 10029, United States
Research Site 40001-370

Tallahassee, Florida, 32308, United States
Research Site 40001-372

Warren, Michigan, 48088, United States
Research Site 40001-374

Bakersfield, California, 93301, United States
Research Site 40001-377

San Antonio, Texas, 78258, United States
Research Site 40001-380

Redding, California, 96001, United States
Research Site 40001-382

Raleigh, North Carolina, 27610, United States
Research Site 40001-385

Wheat Ridge, Colorado, 80033, United States
Research Site 40001-386

Oklahoma City, Oklahoma, 73102, United States
Research Site 40001-387

Brick, New Jersey, 08724, United States
Research Site 40001-394

Williamsburg, Virginia, 23188, United States
Research Site 40001-395

Hershey, Pennsylvania, 17033, United States
Research Site 40001-398

Charlotte, North Carolina, 28277, United States
Research Site 40001-403

Skokie, Illinois, 60077, United States
Research Site 40001-404

Omaha, Nebraska, 68798, United States
Research Site 40001-408

Charlotte, North Carolina, 28273, United States
Research Site 40001-409

Missoula, Montana, 59808, United States
Research Site 40001-412

Great Neck, New York, 11021, United States
Research Site 40001-413

Cleveland, Ohio, 44106, United States
Research Site 40001-414

Franklin, Tennessee, 37067, United States
Research Site 40001-415

Dallas, Texas, 75246, United States
Research Site 40001-417

Annapolis, Maryland, 21401, United States
Research Site 40001-418

Frisco, Texas, 75034, United States
Research Site 40001-419

Westminster, California, 92683, United States
Research Site 40001-421

Mankato, Minnesota, 56001, United States
Research Site 40001-423

Savannah, Georgia, 31406, United States
Research Site 40001-424

Kerrville, Texas, 78028, United States
Research Site 40001-425

Aurora, Colorado, 80014, United States
Research Site 40001-427

Dearborn, Michigan, 48126, United States
Research Site 40001-429

Plantation, Florida, 33317, United States
Research Site 40001-430

Rock Hill, South Carolina, 29732, United States
Research Site 40001-433

La Crosse, Wisconsin, 54601, United States
Research Site 40001-434

San Diego, California, 92123, United States
Research Site 40001-435

Greenville, North Carolina, 17834, United States
Research Site 40001-437

Alexandria, Louisiana, 71303, United States
Research Site 40001-438

Dickson, Tennessee, 37055, United States
Research Site 40001-439

Rocky Mount, North Carolina, 27804, United States
Research Site 40001-440

La Palma, California, 90623, United States
Research Site 40001-442

Southfield, Michigan, 48034, United States
Research Site 40001-443

La Crosse, Wisconsin, 54601, United States
Research Site 40001-448

Lincoln, Nebraska, 68510, United States
Research Site 40001-449

Napa, California, 94558, United States
Research Site 40001-452

Dunwoody, Georgia, 30350, United States
Research Site 40001-455

New York, New York, 10016, United States
Research Site 40001-456

Takoma Park, Maryland, 20912, United States
Research Site 40001-457

Jersey City, New Jersey, 07304, United States
Research Site 40001-462

Peoria, Arizona, 85381, United States
Research Site 40001-463

Rochester Hills, Michigan, 48307, United States
Research Site 40001-466

Baltimore, Maryland, 21237, United States
Research Site 40001-468

Fall River, Massachusetts, 02723, United States
Research Site 40001-473

Las Vegas, Nevada, 89109, United States
Research Site 40001-483

East Point, Georgia, 30344, United States
Research Site 40001-485

Inglewood, California, 06410, United States
Research Site 40001-487

Chandler, Arizona, 85224, United States
Research Site 40011-001

Windsor, Ontario, N8X 5A6, Canada
Research Site 40011-004

Ajax, Ontario, L1S 2J5, Canada
Research Site 40011-005

Windsor, Ontario, N8X 2G1, Canada
Research Site 40011-010

Burlington, Ontario, L7N, Canada
Research Site 40011-011

Vancouver, V5Z 1M9, Canada
Research Site 40011-014

Ottawa, Ontario, K1H 1E4, Canada
Research Site 40011-016

Ajax, Ontario, L1Z 0M1, Canada
Research Site 40011-018

Montreal, Quebec, H4A 3J1, Canada
Research Site 40011-020

Trois-Rivières, Quebec, G9A 4P3, Canada
Research Site 40011-022

Québec, Quebec, G1G 3Y8, Canada
Research Site 40027-004

Pretoria, 0002, South Africa
Research Site 40027-005

KwaZulu, 4001, South Africa
Research Site 40027-006

Mpumalanga, 1050, South Africa
Research Site 40027-007

Durban, 7570, South Africa
Research Site 40027-008

KwaZulu, 4092, South Africa
Research Site 40027-009

Cape Town, 7530, South Africa
Research Site 40027-010

KwaZulu, 4450, South Africa
Research Site 40027-011

Cape Town, 7570, South Africa
Research Site 40027-013

Benoni, 1500, South Africa
Research Site 40027-017

Welkom, 9460, South Africa
Research Site 40027-018

Vereeniging, 1935, South Africa
Research Site 40027-019

Pretoria, 0204, South Africa
Research Site 40027-020

KwaZulu, 4170, South Africa
Research Site 40027-021

Cape Town, 7700, South Africa
Research Site 40027-023

KwaZulu, 4301, South Africa
Research Site 40027-025

Cape Town, 7505, South Africa
Research Site 40027-026

Johannesburg, 2193, South Africa
Research Site 40027-027

KwaZulu, 4301, South Africa
Research Site 40040-001

Constanța, 900002, Romania
Research Site 40040-002

Brasov, 500051, Romania
Research Site 40040-003

Timișoara, 300310, Romania
Research Site 40040-004

Brasov, Brașov County, 50366, Romania
Research Site 40040-006

Cluj-Napoca, Cluj, 400371, Romania
Research Site 40040-007

Cluj-Napoca, 400371, Romania
Research Site 40040-009

Cluj-Napoca, 400162, Romania
Research Site 40040-010

Sângeorgiu de Mureş, 547365, Romania
Research Site 40044-001

Manchester, BL9 0NJ, United Kingdom
Research Site 40044-006

Manchester, M33 4BR, United Kingdom
Research Site 40044-008

Salford, M6 5WW, United Kingdom
Research Site 40044-009

Manchester, M24 4DZ, United Kingdom
Research Site 40044-013

Manchester, M22 4DH, United Kingdom
Research Site 40044-017

Chorley, PR7 7NA, United Kingdom
Research Site 40044-018

Bellshill, ML4 3NJ, United Kingdom
Research Site 40044-019

Liverpool, L22 0LG, United Kingdom
Research Site 40044-020

Manchester, M15 6SE, United Kingdom
Research Site 40044-021

Birmingham, B15 2SQ, United Kingdom
Research Site 40044-022

Enfield, EN3 4GS, United Kingdom
Research Site 40044-024

Preston, PR2 9RB, United Kingdom
Research Site 40044-026

Rochdale, OL11 4AU, United Kingdom
Research Site 40044-034

Stockport, SK8 5LL, United Kingdom
Research Site 40044-036

Manchester, M27 0EW, United Kingdom
Research Site 40044-077

Bollington, SK10 5JH, United Kingdom
Research Site 40044-078

Wythenshawe, M23 9QZ, United Kingdom
Research Site 40044-084

London, E1 1 EQ, United Kingdom
Research Site 40048-001

Będzin, 42-500, Poland
Research Site 40048-002

Katowice, 40-365, Poland
Research Site 40048-005

Lodz, 90-549, Poland
Research Site 40048-006

Giżycko, 11-500, Poland
Research Site 40048-008

Krakow, 31-159, Poland
Research Site 40048-009

Lodz, 90-302, Poland
Research Site 40048-010

Piaseczno, 05-500, Poland
Research Site 40048-012

Trzebnica, 55-100, Poland
Research Site 40048-014

Skierniewice, 96-100, Poland
Research Site 40048-015

Lodz, 90-141, Poland
Research Site 40048-016

Poznan, 61-578, Poland
Research Site 40048-018

Bialystok, 15-044, Poland
Research Site 40048-019

Wroclaw, 51-162, Poland
Research Site 40048-021

Katowice, 40-081, Poland
Research Site 40048-022

Lublin, 20-089, Poland
Research Site 40048-023

Gdansk, 80-214, Poland
Research Site 40048-024

Maków Podhalański, 34-220, Poland
Research Site 40048-027

Krakow, 30-033, Poland
Research Site 40048-031

Ostrowiec Świętokrzyski, 27-400, Poland
Research Site 40048-032

Bialystok, 15-430, Poland
Research Site 40048-033

Krakow, 31-011, Poland
Research Site 40048-039

Rzeszów, 35-205, Poland
Research Site 40048-040

Krakow, 31-864, Poland
Research Site 40052-007

Guadalajara, 044100, Mexico
Research Site 40052-012

San Juan del Río, 76800, Mexico
Research Site 40052-026

Chihuahua City, 31203, Mexico
Research Site 40052-028

Mexico City, 06700, Mexico
Research Site 40054-002

San Miguel de Tucumán, T4000CBC, Argentina
Research Site 40054-008

Buenos Aires, C1426ABP, Argentina
Research Site 40054-010

Mendoza, M5500CCG, Argentina
Research Site 40054-015

Caba, C1121ABE, Argentina
Research Site 40054-016

Mendoza, M5500CBA, Argentina
Research Site 40054-017

Buenos Aires, C1027AAP, Argentina
Research Site 40054-019

Mendoza, M5500AXR, Argentina
Research Site 40054-020

San Miguel de Tucumán, T4000IAJ, Argentina
Research Site 40054-024

San Miguel de Tucumán, C1425BEN, Argentina
Research Site 40054-028

Mendoza, M5501AAJ, Argentina
Research Site 40054-032

Mendoza, M5501GCA, Argentina
Research Site 40054-034

Buenos Aires, B8000JRB, Argentina
Research Site 40054-035

Buenos Aires, B1878FNR, Argentina
Research Site 40054-043

Buenos Aires, C14426ABP, Argentina
Research Site 40054-044

Buenos Aires, B1878FNR, Argentina
Research Site 40054-057

Mendoza, M5506BBH, Argentina
Research Site 40055-001

São Bernardo do Campo, 09715-090, Brazil
Research Site 40055-004

Porto Alegre, 90610-000, Brazil
Research Site 40055-005

Santo André, 09060-870, Brazil
Research Site 40055-007

Blumenau, 89030-101, Brazil
Research Site 40055-009

Santos, 11075-900, Brazil
Research Site 40055-010

Porto Alegre, 91010-006, Brazil
Research Site 40055-011

Campo Largo, 83606-177, Brazil
Research Site 40055-012

Porto Alegre, 90035-074, Brazil
Research Site 40055-015

Belo Horizonte, Brazil
Research Site 40055-025

Salvador, 40060-325, Brazil
Research Site 40055-035

Rio de Janeiro, 22061-080, Brazil
Research Site 40055-036

Curitiba, 80810-100, Brazil
Research Site 40055-043

Curitiba, 80060-900, Brazil
Research Site 40082-003

Anyang-si, 14068, South Korea
Research Site 40082-004

Seoul, 07061, South Korea
Research Site 40082-006

Jeonju, 54907, South Korea
Research Site 40082-007

Busan, 48108, South Korea
Research Site 40082-008

Seoul, 06591, South Korea
Research Site 40082-010

Suwon, 16499, South Korea
Research Site 40082-011

Seoul, 08308, South Korea
Research Site 40082-012

Seoul, 05030, South Korea
Research Site 40082-019

Seoul, 04763, South Korea
Research Site 40082-020

Incheon, 21565, South Korea
Research Site 40082-021

Gwangju, 61469, South Korea
Research Site 40090-002

Adana, 01240, Turkey (Türkiye)
Research Site 40090-003

Ankara, 06560, Turkey (Türkiye)
Research Site 40090-008

Ankara, 06620, Turkey (Türkiye)
Research Site 40090-009

Ankara, 06930, Turkey (Türkiye)
Research Site 40090-011

Istanbul, 34844, Turkey (Türkiye)
Research Site 40090-012

Konak, 35110, Turkey (Türkiye)
Research Site 40090-013

Mersin, 33110, Turkey (Türkiye)
Research Site 40090-016

Center, 17020, Turkey (Türkiye)
Research Site 40090-017

Antalya, 07400, Turkey (Türkiye)
Research Site 40090-018

Ankara, 06230, Turkey (Türkiye)
Research Site 40090-019

Bornova, 35100, Turkey (Türkiye)
Research Site 40090-020

Istanbul, 34020, Turkey (Türkiye)
Research Site 40090-021

Ankara, 06230, Turkey (Türkiye)
Research Site 40090-022

Tekirdağ, 59100, Turkey (Türkiye)
Research Site 40090-024

Ankara, 06230, Turkey (Türkiye)
Research Site 40090-024

Pendik, Turkey (Türkiye)
Research Site 40090-025

Ankara, 06560, Turkey (Türkiye)
Research Site 40090-026

Istanbul, 34750, Turkey (Türkiye)
Research Site 40380-001

Ternopil, 46023, Ukraine
Research Site 40380-002

Chernivtsi, 58001, Ukraine
Research Site 40380-003

Vinnytsia, 21001, Ukraine
Research Site 40380-004

Ivano-Frankivsk, 76018, Ukraine
Research Site 40380-005

Zhytomyr, 10002, Ukraine
Research Site 40380-007

Kyiv, 03038, Ukraine
Research Site 40380-008

Vinnytsia, 21029, Ukraine
Research Site 40380-009

Ivano-Frankivsk, 76008, Ukraine
Research Site 40380-010

Kyiv, 03038, Ukraine
Research Site 40380-011

Kyiv, 03057, Ukraine
Research Site 40380-012

Kyiv, 03038, Ukraine
Research Site 40380-013

Kyiv, 03115, Ukraine
Research Site 40380-014

Ivano-Frankivsk, 76019, Ukraine
Research Site 40380-015

Kyiv, 03049, Ukraine
Research Site 40380-016

Lutsk, 45634, Ukraine
Research Site 40380-017

Ivano-Frankivsk, 76018, Ukraine
Research Site 40380-018

Kyiv, 03037, Ukraine
Research Site 40380-019

Kyiv, 02002, Ukraine
Research Site 40380-020

Vinnytsia, 21018, Ukraine
Research Site 40380-021

Chernivtsi, 58022, Ukraine
Research Site 40380-022

Vinnytsia, 21029, Ukraine
Research Site 40787-345

Vega Baja, 00694, Puerto Rico
Research Site 40787-360

San Juan, 00927, Puerto Rico
Research Site 40787-365

Guaynabo, 00968, Puerto Rico
Research Site 40787-383

San Juan, 00918, Puerto Rico
Research Site 40787-388

San Juan, 00907, Puerto Rico
Research Site 40787-390

Ponce, 00717, Puerto Rico
Research Site 40787-405

San Juan, 00918, Puerto Rico
Research Site 40866-003

Taipei, 11217, Taiwan
Research Site 40886-001

Kaohsiung City, 807, Taiwan
Research Site 40886-004

New Taipei City, 220, Taiwan
Research Site 40886-005

Taichung, 40403, Taiwan
Research Site 40886-006

New Taipei City, 23561, Taiwan
Research Site 40886-007

Taichung, 40705, Taiwan
Research Site 40886-008

Taipei, 110, Taiwan
Research Site 40886-009

Taipei, 11240, Taiwan
Research Site 40886-010

Taipei, 100, Taiwan
Research Site 40972-001

Jerusalem, Israel
Research Site 40972-002

Petah Tikva, 4941492, Israel
Research Site 40972-004

Haifa, 3436212, Israel
Research Site 40972-005

Haifa, 3109601, Israel
Research Site 40972-008

Beersheba, 8410101, Israel
Research Site 40972-009

Kfar Saba, 4428164, Israel
Research Site 40972-010

Ashkelon, 7830604, Israel
Research Site 40972-011

Ramat Gan, 5262000, Israel
Research Site US-40001-038

Edmond, Oklahoma, 73034, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.